Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

2.8K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CK2 inhibition suppresses glial inflammation in models of neuroinflammation and neurodegeneration.

Nature communications·2026
Same author

DNA damage drives a unique, Alzheimer's disease-relevant senescent state in neurons.

bioRxiv : the preprint server for biology·2026
Same author

Adult neurogenesis: New neurons, new opportunities.

Cell stem cell·2026
Same author

Retrotransposon Activation in the Aged and Alzheimer's Disease Brain Examined by Nanopore Long-read DNA Sequencing.

bioRxiv : the preprint server for biology·2026
Same author

Omnidirectional 3D Printing of Anisotropic Nanofibrous Peptide Hydrogels.

bioRxiv : the preprint server for biology·2025
Same author

The need for a global effort to attend to human neural organoid and assembloid research.

Science (New York, N.Y.)·2025
Same journal

Fast-conducting mechanonociceptors uniquely engage reflexive and affective pain circuitry to drive protective responses.

Neuron·2026
Same journal

Sparse component analysis: A method that uncovers separable computations within neural population activity.

Neuron·2026
Same journal

Spatiomolecular mapping reveals anatomical organization of heterogeneous cell types in the human nucleus accumbens.

Neuron·2026
Same journal

TGF-β1-induced endothelial transcytosis drives blood-brain barrier leakage during aging.

Neuron·2026
Same journal

Image space opens up for visual neuroscience.

Neuron·2026
Same journal

Septal GLP-1 receptors control alcohol taking and seeking.

Neuron·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Improving and accelerating drug development for nervous system disorders.

Diana E Pankevich1, Bruce M Altevogt1, John Dunlop2

  • 1Forum on Neuroscience and Nervous System Disorders, Institute of Medicine, Washington, DC 20001, USA.

Neuron
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Neuroscience advances offer hope for nervous system disorders, but drug development faces significant hurdles. Workshops convened experts to discuss challenges and strategies for improving translational neuroscience and accelerating drug discovery.

More Related Videos

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

4.5K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.7K

Related Experiment Videos

Last Updated: Apr 20, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

4.5K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.7K

Area of Science:

  • Neuroscience
  • Translational Medicine
  • Drug Discovery and Development

Background:

  • Neuroscience research is advancing, with potential to alleviate nervous system disorder burden.
  • Significant challenges impede effective drug discovery, development, and translation for neurological conditions.

Purpose of the Study:

  • To identify and discuss key scientific and logistical challenges in nervous system drug development.
  • To explore strategies for accelerating the translation of neuroscience discoveries into effective therapies.

Main Methods:

  • Public workshops convened by the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders.
  • Inclusion of diverse stakeholders: industry, government (research and regulatory), academia, and patient groups.

Main Results:

  • Key challenges identified include understanding disease mechanisms, target validation, predictive models, biomarkers, regulatory pathways, data reliability, and collaboration.
  • Discussions aimed at generating actionable strategies to overcome these translational barriers.

Conclusions:

  • Addressing identified challenges is crucial for advancing nervous system drug development.
  • Collaborative efforts among diverse stakeholders are essential to improve translational neuroscience and reduce the impact of neurological disorders.